Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
|
EQS-News: Pentixapharm Holding AG
/ Key word(s): Conference/Scientific publication
Berlin, Germany, April 25, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, will present new pre-clinical data on its novel antibody GT-008 at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago. The presentation highlights GT-008’s unique glycan-dependent binding mechanism, a key advancement for immunotherapy and radioconjugate development. GT-008 is a first-in-class, glycan-dependent monoclonal antibody targeting CD24, a surface protein implicated in tumor progression. By recognizing a tumor-associated O-glycoform of CD24—limited in healthy tissue—the antibody shows high affinity and specificity for cancer cells, while binding to CD24-expressing healthy cells is strongly reduced. This lowers the potential for on-target/off-tumor activity, overcoming key limitations of conventional CD24-targeting antibodies and other binding modalities. GT-008 retains strong binding and internalization in a range of solid tumors, including endometrial, breast, ovarian, and squamous cell carcinoma of the skin. Its format enables flexible payload integration—ranging from cytotoxics to radiotherapeutics—supporting diverse therapeutic modalities. An in vitro and in vivo proof-of-concept study using a radiolabeled version is currently underway—laying the groundwork for what could become the first radioconjugated antibody in Pentixapharm’s development pipeline. Presentation Details:
The poster can be found here: Link
About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based, first-in-class radiopharmaceuticals with strong differentiation and commercialization potential across high-need diagnostic and therapeutic areas. Its pipeline comprises CXCR4-targeted compounds in clinical development and a portfolio of early-stage radionuclide-antibody conjugates, aimed at treating hematologic malignancies, solid tumors, and diseases of the cardiovascular, endocrine, and immune systems.
For more information, please contact: Pentixapharm Holding AG
25.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2124644 |
| End of News | EQS News Service |
|
|
2124644 25.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.